Docetaxel

Key facts

Invented name
Taxotere
Active substance
docetaxel
Therapeutic area
Oncology
Decision number
P/22/2008
PIP number
Docetaxel
Pharmaceutical form(s)
Concentrate and solvent for solution for infusion
Condition(s) / indication(s)
Nasopharyngeal carcinoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Applicant: Aventis Pharma SA
E-mail: sylvie.gabriel@sanofi-aventis.com
Country: France
Phone: +33 153774152
Fax: +33 153774133
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating